Legend Biotech Corporation closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including Legend Biotech's existing autologous CAR-T cell therapy candidate, LB2102 (NCT05680922). Under the terms of the license agreement closed on January 3, 2024, Legend Biotech will receive a $100 million upfront cash payment.